Pneumonia remains a common cause of morbidity and mortality in the US. Although, communityacquired pneumonia (CAP) has traditionally been considered an acute process, more recently, data have emerged showing that patients surviving an episode of CAP are at increased risk of death long after hospital discharged. In this descriptive review, we examine the current knowledge of long-term mortality and propose a hypothesis explaining the pathogenesis of long-term mortality in patients with CAP.
Introduction
Pneumonia remains a common cause of morbidity and mortality in the US. Published data from the Centers for Disease Control and Prevention ranks pneumonia as the first leading cause of death from infectious diseases and eight from all diseases [1] . A total of 53,282 individuals died of pneumonia in 2013 [2] . Based on the most recent report from the Agency for Healthcare Research and Quality, pneumonia was the second most common reason for hospital admissions after liveborn (newborn) in 2011 with over 1.1 million hospitalizations [3] . Another study reported 3.9 million hospitalizations due to pneumonia between 2007 and 2011 [4] . CAP has traditionally been considered an acute process that, once resolved, has no further impact on patients' survival. Studies evaluating clinical outcomes have focused on early mortality; either during hospitalization or within 30 days after the initial episode. Early mortality rates range from 4 -30% depending on the studied population, treatment setting, and severity of disease [5] [6] [7] [8] . Considering this short-term impact on patients' outcomes, CAP research has been traditionally focused on improving short-term outcomes such as time to clinical stability, clinical failure, length of stay, in-hospital mortality, and 30-day mortality. Different immunomodulatory strategies including corticosteroids, antiplatelets, and specific antibiotics have been considered as interventions, sometimes in a particular setting or type of patient [9] [10] [11] [12] .
More recently, data have emerged showing that patients surviving an episode of CAP are at increased risk of death long after hospital discharge [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . In this descriptive review, we examine the current knowledge of long-term mortality and propose a hypothesis explaining the pathogenesis of long-term mortality in patients with CAP. A search was performed using MEDLINE/PubMed through April 2017 with the following keywords: community-acquired pneumonia, mortality, long-term, outcomes.
In an attempt to standardize the follow-up period, we only included in this review original studies that either reported mortality at 1 year or had enough data to estimate this information.
Current Literature
A total of 21 articles reporting long-term mortality data after hospitalizations for CAP were identified, with rates up to 10 or more years ranging between 17 and 50%, and up to 2-3 times higher than patients without a hospitalization for CAP . After the initial review, we identified 15 articles reporting 1-year mortality rates. In Table 1 we summarized studies describing 1-year mortality in patients with CAP [13] [14] [15] [16] [17] [18] [19] . In Table 2 we summarized studies comparing 1-year mortality in patients with CAP to control groups [20] [21] [22] [23] [24] [25] [26] [27] . Figure 1 represents the reported 1-year mortality for hospitalized patients with CAP for each study. These studies suggest that for all hospitalized patients with CAP, the 1-year mortality is approximately 30 to 35%. For hospitalized patients without CAP, the 1-year mortality is approximately 20 to 25%, whereas for those patients not hospitalized and not developing CAP the 1-year mortality was even lower, ranging between 1 and 5%. In hospitalized patients with CAP, there is a 10% increased risk for 1-year mortality in relation to hospitalized patients with other medical conditions. Follow-up periods vary among the different published studies evaluating long-term mortality. This, along with differences in the studied population, makes comparisons difficult. We believed that different exclusion criteria among the studies is the likely explanation for the wide range mortality reported in the studies. 
A hypothesis to explain long-term mortality
Chronic inflammation has been associated with aging and early death; a process described as "inflammaging" [34] . Persistent elevated levels of inflammatory cytokines have been documented in patients with CAP at time of hospital discharge. The increased long-term mortality after CAP may be mediated by an inflammatory response that persists after hospital discharge, adds to the inflammaging process, and accelerates the progression of medical comorbidities and early death [35, 36] . Months after hospital discharge, the primary cause of death may be cardiovascular disease or other underlying comorbidities. The prior episode of CAP would influence death by worsening the underlying comorbidity. Figure 2 is a schematic representation indicating the projectedlife expectancy of a 50-year old patient who is hospitalized due to CAP (Figure 2: point 1) . After the patient is discharged from the hospital, the projected life expectancy changes to line B and is considerably decreased (Figure 2: point 2) . Mortality rates for patients with CAP have not significantly decreased since the 1950s [37] . Adjunctive therapies such as macrolides, statins, corticosteroids, and antiplatelet agents have been studied in an attempt to improve short-term outcomes [38] . Despite the knowledge of higher mortality rates long after hospitalization for CAP, no studies evaluating the impact of adjunctive therapies on longterm outcomes have been conducted. It can be speculated that medications able to decrease chronic inflammation may reduce long term mortality in hospitalized patients with CAP. 
Conclusions
Improving the clinical outcomes of hospitalized patients with CAP is of paramount importance for patients, as well as clinical investigators. The recent recognition of long-term mortality associated with CAP is opening a new frontier for clinical research in the field. We need studies to better define the underlying pathophysiology explaining the association of CAP with long-term mortality. Intervention to improve clinical outcomes in patients with CAP have frequently been tested in short term 30-day studies, since CAP was considered an acute problem without chronic implications. We need a new paradigm to design clinical trials to test interventions that may reduce long-term mortality.
